TrialReviewer
← All briefs

August 30, 2026 · Sunday

1 Key Question · 2 Research Highlights · 3 Quick Updates

Right after a heart attack, does starting a potent lipid-lowering injection and driving bad cholesterol to very low levels mean fewer events?

Target attainment did double (LDL target attainment 82% vs 40%), but death or cardiovascular hospitalization within one year did not differ between the two arms (14.6% vs 15.4%). "Reaching the cholesterol target" is not the same as "fewer events"; the benefit of lipid lowering may take longer to emerge.

JAMA（ESC 2026） · 2026-08-29

Who it applies to

Adults with acute myocardial infarction scheduled for PCI (stent placement).

What it showed

Starting evolocumab (a PCSK9 inhibitor) before stenting gave a clearly higher rate of LDL target attainment at 12 months (82% vs 40%) and faster attainment.

What remains unknown

The primary clinical outcome (death or cardiovascular hospitalization) did not differ between the two arms within one year; only a post hoc per-protocol analysis suggested possible benefit, which is hypothesis-generating and requires longer follow-up for confirmation.

Population
Adults with acute myocardial infarction scheduled for PCI; 2161 patients (AMUNDSEN randomized trial, presented at ESC 2026 with simultaneous publication in JAMA).
Intervention
Evolocumab (a PCSK9 inhibitor) started before PCI.
Comparator
Standard lipid-lowering therapy.
Applicability
Limited to patients with acute myocardial infarction undergoing PCI; not extrapolated to non-acute settings or to patients not undergoing PCI.
Primary endpoint
Biological endpoint: LDL reduction ≥50% and LDL <55 mg/dL at 12 months; clinical endpoint: all-cause death or unplanned cardiovascular hospitalization.
Key results
LDL target attainment 82% vs 40%; time to attainment 9 vs 19 weeks; clinical endpoint 14.6% vs 15.4%, no significant difference. Post hoc exploratory per-protocol analysis 10.2% vs 14.3% (hypothesis-generating; no conclusion can be drawn from it).
Limitations
Follow-up of about 12 months may be insufficient for the long-term benefit of lipid lowering to emerge; clinical benefit was seen only in the post hoc per-protocol analysis; the biological endpoint is a surrogate measure.
Source
AMUNDSEN trial; JAMA, 2026-08-29 (simultaneous with ESC 2026).

Research

Worth reading this week.

MRI scar to guide defibrillator implantation in "gray zone" heart failure patients: no significant difference overall

Journal

353 patients with ejection fraction 36–50% and myocardial scar on MRI; randomized to ICD or an implantable loop recorder. Primary endpoint (sudden cardiac death or major ventricular arrhythmia) 7.8% vs 9.2% (HR 0.76, 95% CI 0.37–1.58, not significant); the subgroup aged under 70 and the secondary endpoint of "sudden death alone" suggested benefit, but these are exploratory.

JAMA（ESC 2026） · 随机对照 · ESC 2026

Digital reminders to improve statin refills: a difference, but of limited magnitude

Journal

ADHERE-ASCVD randomized trial; digital outreach to promote refills in patients with atherosclerotic disease and low adherence produced a small improvement in refills, but the gap remained substantial (editorial: small benefit, persistent gap). See the original article for specific values.

JAMA（ESC 2026） · 随机对照 · ESC 2026

Quick News

Signals worth watching.

  • Public health · Infectious disease · Measles cases in the Americas have reached 3 times the total for all of 2025, and PAHO has issued a warning.

    Media

    JAMA Medical News · 2026-08-28

  • Guidelines · Cardiovascular · New ACC scientific statement: cardiovascular care of older patients should incorporate assessment of cognition and frailty.

    Media

    JAMA Medical News · 2026-08-28

  • Oncology · Lung cancer · Selpercatinib as adjuvant therapy for early-stage RET fusion-positive non-small cell lung cancer (original research in NEJM).

    Journal

    NEJM · 2026-08-28

Sources

Every claim is traceable.